Table 3 Baseline characteristics of patients with OMBC stratified by final outcome.
Characteristic | Alive (N = 17) | Expired (N = 20) | Lost to follow-up (N = 18) | P-value |
|---|---|---|---|---|
Age (in years) | 48.1 (43.4,52.8) | 49.5 (44.8,54.1) | 53.7 (47.7,59.7) | 0.30 |
Postmenopausal at diagnosis | 66.7% (10) | 75% (15) | 76.5% (13) | 0.80 |
Size of lesion (cm) | 6.14 (3.9,8.4) | 5.8 (4.5,7.1) | 9.1 (5.6,12.6) | 0.14 |
T stage | 0.61 | |||
Tis-T2 | 23.5% (4) | 10% (2) | 11.1% (2) | |
T3–T4 | 76.5% (13) | 90% (18) | 88.9% (16) | |
N stage | 0.27 | |||
N0–1N1 | 82.3% (14) | 50% (10) | 55.6% (10) | |
N2–N3 | 17.7% (3) | 50% (10) | 44.4% (8) | |
Type of surgery | 0.17 | |||
Breast conserving | 17.7% (3) | 0% (0) | 11.1% (2) | |
Mastectomy | 82.3% (14) | 100% (20) | 88.9% (16) | |
Histological type | 0.95 | |||
Invasive Ductal | ||||
Carcinoma (IDC) | 82.3% (14) | 90% (18) | 88.2% (15) | |
Non-IDC | 17.7% (3) | 10% (2) | 11.8% (2) | |
Histological grade | 0.08 | |||
Low | 0% (0) | 10% (2) | 0% (0) | |
Moderate | 35.3% (6) | 55% (11) | 27.8% (5) | |
High | 64.7% (11) | 20% (4) | 38.9% (7) | |
Lymphovascular invasion | 11.8% (2) | 40% (8) | 27.8% (5) | 0.31 |
Hormone receptor positivity | 70.6% (12) | 70% (14) | 58.8% (10) | 0.71 |
Her2 receptor positivity | 29.4% (5) | 35% (7) | 22.2% (4) | 0.77 |
Chemotherapy | 0.85 | |||
Initial | 23.6% (4) | 10% (2) | 5.6% (1) | |
Adjuvant | 5.9% (1) | 5% (1) | 0% (0) | |
Radiation | 47.1% (8) | 70% (14) | 50% (9) | 0.80 |
